Bioinvent International AB Mutual Funds

Health Care & Life Sciences » Biotechnology | Bioinvent International AB

Bioinvent International AB | Mutual Funds

Mutual Funds that own Bioinvent International AB

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Rhenman & Partners Fund - Healthcare Equity L/S

10,028,316

2.86%

-20,000

0.19%

12/31/2017

MFS Meridian Funds - European Smaller Companies Fund

4,350,077

1.24%

0.09%

07/31/2018

1,850,000

0.53%

0.3%

07/31/2018

SEB Sverige Indexfond

985,508

0.28%

0.01%

12/31/2017

DFA Continental Small Company Series

517,329

0.15%

-48,490

01/31/2018

DFA International Core Equity Portfolio

229,139

0.07%

04/30/2018

Skandia Sverige Exponering

138,268

0.04%

0.01%

07/31/2018

Catella Sverige Index

77,034

0.02%

0.01%

08/31/2018

Nomura Multi Managers Fund III - European Equity

38,894

0.01%

-15,874

0.02%

12/31/2016

Handelsbanken Sverigefond Index

122

-1,221,841

08/31/2018

About Bioinvent International AB

View Profile

Address	Sölvegatan 41 Lund SN 223 70 Sweden
Employees	-
Website	http://www.bioinvent.com
Updated	07/08/2019
BioInvent International AB engages in the research and development of immuno-regulatory antibodies to treat cancer. Its clinical programs include BI-1206 for non-Hodgkin's lymphoma and chronic lymphatic leukaemia; TB-403 for paediatric brain tumors; and THR-317 for diabetic macular edema. Its technology platforms consist of F.